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1. Controlled drug delivery system
1. 1 Introduction
    Over the past twenty-five years, as the expense and complication involved 
in marketing new drug entities have increased with concomitant recognition 
of the therapeutic advantage of controlled drug delivery system. There are 
several seasons for the attractiveness of these dosage forms. It is generally 
recognized  that  for  many  disease  states,  a  substantial  number  of 
therapeutically  effective  compounds  already  exist.  Side  effects  or  the 
necessity to administer the compound in a clinical setting, however, often 
limits the effectiveness of this drugs.1
            The goal in designing controlled drug delivery systems is to reduce 
the  frequency  of  dosing  and  increase  effectiveness  of  the  drug  by 
localization at  the site of action .Reducing the dose required (or)  providing 
uniform drug delivery.
        Controlled release drug administration means not only prolonged 
release,  but also implies  predictability and reproducibility of drug release 
kinetics.  Controlled drug delivery system is the one, which delivers the drug 
at a predetermined rate, systematically, for a specific period of time .2
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FIGURE 1 Theoretical Illustration Comparing Blood Drug  Concentration 
profiles Of A Controlled-Release Drug Delivery System And Conventional 
Dosage Forms Via Various Routes Of Administration.
Figure  1 show  comparative  blood  drug  level  profiles  obtained  from 
administration  of  conventional,  controlled  as  well  as  prolonged  release 
dosage  forms.  Thus,  the  conventional  tablet  or  capsule  provides  only  a 
single and transient burst of drug. As long as the amount  of drug is above 
the  minimum  effective  concentration,  a  pharmacological  response  is 
observed  problems occur  when the  therapeutic  range is  very  narrow or 
when the peak is greater than the upper limit of this of this  range. Indeed, 
one  of  the  main  purposes  of  controlled  release  to  improve  safety  and 
minimize side effects of the drug by reducing fluctuations in drug level.3
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 MERITS OF CONTROLLED DRUG DELIVERY SYSTEM4  
 
1. The potential merit that a controlled release drug delivery system may 
bring to us can be appreciated by a consideration of prolonged and 
efficient delivery of therapeutically effective dosages, and localization 
of therapy.
2. The  "peak  and  valley'  pattern  is  more  striking  for  drugs  with 
biological  half-life  less  than4hrs.   Which  can  be  over  come  by 
controlled release drug delivery system
3. It provides maximum utilization of drug enabling reduction in total 
amount of dose administered.
4. Improved patient  convenience and compliance  due to less  frequent 
drug administration.
5. Reduction  in  fluctuation  in  steady  state  levels  and  therefore  better 
control of disease condition and reduced intensity of local or systemic 
side effects.
6. Increased safety margin of high potency drugs due to better control of 
plasma levels.
7. Reduction in health care cost through improved therapy, shorter time 
period,  less  frequency of  dosing and reduction in  personal  time  to 
dispense, administer and monitor patients.
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DEMIRITS OF CONTROLLED DRUG DELIVERY SYSTEM5
 
1. Decreased systemic availability in comparison to immediate release 
conventional  dosage  forms;  this  may  due  to  incomplete  release, 
increased  first  pass  metabolism,  increased  stability,  insufficient 
residence  time  for  complete  release,  site-specific  action,  pH-
dependant solubility, etc.
2. Possibility of dose dumping due to food, physiologic or formulation 
variables or chewing or grinding of oral formulation by the patient 
and thus, increased risk of toxicity.
3. Retrieval  of  drug  is  difficult  in  case  of  toxicity,  poisoning  or 
hypersensitivity reaction.
4. Reduced  potential  for  dosage  adjustment  of  drugs  normally 
administered in varying strengths. 
5. It is higher cost of formulation.
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                 1. 2   TRANSDERMAL  DRUG DELIVERY SYSTEM
 
     For many decades medication of acute disease as well as a chronic illness 
has  been  accomplished  dosage  forms.  Like  tablets,  capsules,  ointments, 
aerosol,  injectables  and  suppositories,  as  carrier,  recently  a  technical 
advancement have resulted in the development of new techniques of drug 
delivery  which  includes  transdermal  drug  delivery  system.  Several 
transdermal  drug  delivery  systems  have  been  developed  to  achieve  the 
objective  of  systemic  medication  through  topical  application  on the  skin 
surface 4.
     The principle of transdermal drug delivery system is that they could 
provide  controlled  drug  delivery  (have  constant  drug  concentration  in 
plasma) over a prolonged period of time. It is anticipated that transdermal 
drug delivery system can be designed to input drugs at appropriate rates to 
maintain suitable plasma drug levels for therapeutic efficacy,  without the 
periodic sojourns into plasma concentration that would accompany toxicity 
(or) lack of efficacy. 
     Transdermal delivery of antihypertensive is one of the prime focus areas 
of  drug  delivery  systems.  Various  antihypertensive  such  as  metoprolol, 
clonidine,  propranalol,  bupranolol,  isosorbide  dinitrite,  verapamil, 
nifedipine,  etc.,  have  been  studied  for  their  suitability  in  transdermal 
therapeutic systems.
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ADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEMS2 
 
1. Avoids problems associated with gastro-intestinal absorption due to 
pH enzymatic activity, and drug food interactions.
2. It is a substitute for oral route.
3. Avoid the risks and inconveniences of I.V therapy.
4. Provides predictable extended duration of activity.
5. Extends the activity of drug with short half-life.
6. Multilayer therapy with single application.
7. Provides capacity to terminate.
8. Minimize inter and intra patient variation.
9. Provides suitability by self-administration.
10.Reduces daily dosing, thus improving patient compliance.
11.Enhance therapeutic efficacy, reduce side effects due to optimization 
of blood concentration –time profile and elimination of pure entity of 
drugs into systemic circulation.
               
 LIMITATIONS OF TRANSDERMAL DRUG DELIVERY SYSTEMS8
1. Difficulty of permeation through human skin: 
 In addition to physical barrier, human skin functions as a 
chemical  barrier.   The  outer  most  layer  of  skin,  the 
stratum corneum is an excellent barrier to all chemicals 
including  drugs.  If  drug  requirements  are  more  than 
10mg per day the transdermal delivery will be difficulty. 
Only relatively potent  drugs can be given through this 
route.
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2. Skin Irritation: 
• Skin  irritation  or  contact  dermatitis  due  to 
excipients and enhancers of the drug system used 
for increasing percutaneous absorption is another 
major limitation.
3. Clinical Need: 
• It has to be examined carefully before developing a 
transdermal product.
                       
      1.3  TYPES OF TRANSDERMAL DRUG DELIVERY SYSTEMS
     Several approaches can be effectively utilized to control the release of 
systematically active drugs for permeation at a programmed rate through the 
skin tissues.  The successfully launched commercially available transdermal 
drug delivery systems may be classified into four types, depending on the 
technological approach9.
 Membrane  permeation  controlled  transdermal  therapeutic 
system;  (Drugs  tried  under  this  are:  Scopolamine  and 
Nitroglycerine).
 Adhesive  dispersion  type  transderrmal  system.  (Drugs  tried 
under this is Nitroglycerine).
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 Micro  reservoir  dissolution  controlled  transdermal  system 
(Drug tried under this is Nitroglycerin
 
 
MICRORESERVOIR TRANSDERMAL DRUG DELIVERY SYSTEM 
     This  is  a  hybrid  of  the  reservoir  and  matrix  dispersion  type  drug 
delivery systems. In this the drug reservoir is formed by first suspending the 
drug  solids  in  the  aqueous  solution  of  a  water  soluble  polymer.(eg. 
Polyethylene glycol) and then dispersing the drug suspension in a lipophilic 
polymer, by high shear mechanical force to form thousands of unleachable 
microscopic spheres of drug reservoir.  This is thermodynamically unstable 
dispersion is quickly stabilized by immediately cross linking the polymer 
chains in situ.  Thus producing a medicated polymer disc with a constant 
surface area and a thickness. 
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Figure No.2 Microreservoir Transdermal Drug Delivery System
  
MATRIX DIFFUSION TRANSDERMAL DRUG DELIVERY 
SYSTEM
 
  
Here, the drug reservoir is formed by homogenously dispersing the 
drug solids  in  a  hydrophilic  or  lipophilic  polymer  matrix,  the  medicated 
polymer is then molded into a medicated disc with a defined surface area 
and  controlled  thickness.  This  drug  reservoir  containing  polymer  disc  is 
mounted to an occlusive base plate in a compartment fabricated from a drug 
impermeable  plastic  backing.  The  adhesive,  in  this  is  spread  along  with 
circumference of the patch to form an adhesive rim.
                    
 
Figure No.3 Matrix Diffusion Transdermal Drug Delivery System
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MEMBRANE MODERATED SYSTEM
 
 In  membrane  moderated  systems  the  drug  reservoir  is  totally 
encapsulated in a shallow compartment molded from a drug impermeable 
metallic plastic laminate and a rate controlling polymeric membrane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No.4 Membrane Moderated System
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ADHESIVE DIFFUSION CONTROLLED SYSTEM:
 
 
In this system the drug reservoir  is  formulated by directly dispersing the 
drug in an adhesive polymer on a flat sheet of drug impermeable backing to 
form a thin drug reservoir  layer.  On the top of  the  drug reservoir  layer, 
layers  of  non-mediated  rate  controlling  adhesive  polymer  of  constant 
thickness  are  applied  to  produce  an  adhesive  diffusion-controlled  drug 
delivery system
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No.5 Adhesive Diffusion Controlled System
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Table. No.1 Commercially Available Transdermal Therapeutic Systems
   
Drug/ 
Manufacturer
    Trade        
     Name
 
  Duration     Type 
     of
 System
Therapeutic
        Use
 
Scopolamine
       Alza
       Ciba
Transderm - 
Scop
      2 days Reservoir Alleviate motion 
sickness.
Nitroglycerine 
      Alza/Ciba
      Hercom
      Searle
       Key
      Wyeth
Transderm –
Nitro
NTS
Nitrodisc
Nitro-dur
Deponite
      1 day  
Reservoir
   Matrix
   Matrix
   Matrix
 Sandwich
 
Treatment and 
prevention of 
Angina.
Isosorbide 
dinitrate
        Nitro electric
        industrial
Frandol Tape       1 day Matrix Treatment and 
prevention of 
Angina.
Clonidine
      Boehringer
      Ingelheim
Catpres -TTS       7 days Reservoir Treatment of 
hypertension.
Estradiol
      Ciba-Giegy
       Parke-davis
Estraderm       3 days Reservoir Relief of post-
menopausal 
symptoms.
Nicotine1
        Alza
        Ciba-Giegy
Nicoderm
  Habitrol
   prostep
      1 day Reservoir
  Matrix
  Matrix
Aid in smoking 
cessation.
 Fentanyl
         Janssens     
 
Duagesic       3 days Reservoir
   Matrix
  Relief from 
moderate severe 
pain.
 Ketoprofen 2  
       Pacific 
Pharmaceuticals
Ketopatch      1 day     Matrix Analgesic and 
anti-inflammatory.
 
 1   The product available in India  [Transderm – TTS; CIBA-GIEGY; 
Top nitro; FULFORD(India)].
2.    The product is very recently launched in India.
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  1.4 NOVEL METHODS IN TRANSDERMAL DRUG DELIVERY
  
  Various Methods Have Been Attempted To Enhance Transport
 
  
1. Penetration enhancers
2. Iontophoresis
3. Electroporation
4. Sonophoresis
5. Microfabricated microneedles and microchips.
Figure No.6 Various Methods for the TDDS
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PENETRATION ENCHANCERS APPROACH
An ideal enhancer should be pharmacologically, inactive, non-irritant 
and should not damage the skin irreversibly. The effects of an enhancer on 
the  permeation  of  a  drug  usually  depend  upon  the  physico-chemical 
characteristics  of  the  permeate  as  well  as  the  enhancer  molecule.  The 
penetration of the enhancers into the stratum corneum is a basic requirement 
for their efficacy. It is possible to facilitate the penetration of the drug by 
appropriate  pretreatment  of  the  skin  with  penetration  enhancer.  The 
lipoprotein  partitioning  theory  of  Barry  offers  the  most  acceptable 
explanation  for  the  skin  with  penetration  enhancers  and  the  stratum 
corneum. Accordingly, the main reason for enhancement includes:
 
  Interactions with the intercellular lipids and intracellular keratin.
  Increased  penetration  of  high  amounts  of  enhancer  or  cosolvent 
into the stratum corneum for to the improved dissolving capacity of 
the  barrier  to  the  drugs.  Many  of  the  chemical  enhancers  such  as 
dimethyl  sulfoxide,  surfactants,  alcohols,  urea,  and  its  derivatives 
have  been  screened  for  their  penetration  enhacement.  The  adverse 
effects caused by some of these enhancers restricts there use widely11. 
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IONTOPHORESIS TECHNOLOGY
    Iontophoresis  is  a  process  or  technique  involving the  transport  of 
ionic or charged molecules into a tissue by the passage of direct or periodic 
electric  current   through  an  electrolyte  solution  containing   the  ionic 
molecules  to  be  delivered  using  an  appropriate  electrode  polarity.  The 
process involves the transfer of ions into the body by an electromotive force. 
Ions with positive charge are driven into the skin at the anode and those with 
the negative charge at the cathode. In the conventional topical treatment by 
iontophoresis,  the  drug  is  administrated  through  an  electrode  having  the 
same charge as the drug and a return electrode opposite in charge to the drug 
is placed at a neutral site on the body surface. The operator then selects a 
current intensity below the pain threshold level of the patient and allows the 
current to flow for an appropriate period of time.
    The current intensity should be increased slowly, maintained for the 
length of the treatment and decreased slowly at the end of the treatment. The 
current  must  have within comfortable  toleration of the patient.  A current 
destiny less than 0.5mA/sq.cm, of the electrode surface has been found to be 
tolerated by the patient. Interposition of a moist pad between the electrode 
plate and the skin is necessary for making a perfect contact, preventing any 
skin  burns,  overcoming  skin  resistance  and  protecting  the  skin  from 
absorbing a caustic metallic compound formed on the metal plate surface. It 
is  important  that,  the drug be  applied  through the  electrode  with  correct 
polarity may not result in penetration of the drug. The electrode must not 
come in any direct contact with skin as it may cause burns.
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   Iontophoresis  was  found  to  be  widely  used  in  several  clinical 
situations; Iontophoretic delivery of ionizable drugs like, propranolol across 
excised  human  skin  from  rabbit,  pig  and  humans  has  been  reported. 
Iontophoretic delivery of a weakly basic  analgesic,  oxycodone across the 
excised skin from human and several animals was investigated using pulse 
current  delivered  from  a  newly  developed  transdermal  iontotherapeutic 
system66 .
ELECTROPORATION TECHNOLOGY
   Electroporation  or  electropermeabilization  involves  changes  in 
membrane of cell due to application of transmembrane voltages. The change 
in the membrane involves; structural rearrangement and conductance leading 
to  temporary  loss  of  semipermeability  of  cell  membranes.  Suggesting 
formation  of  pores.   The  pulses  are  normally  used  on  the  unilamellar 
phospholipids  bilayers  of  cell  membranes.  Approximately  100 
multilammeller bilayer of the stratum corneum need about 100V pulses for 
electroporation or 1V per bilayer.  Electroporation of skin takes place at high 
transdermal voltage (100V or more). There is considerable indirect evidence 
that high voltage pulses cause changes in the skin structure.
    Electroporation is  a technique in which the drug encapsulated in 
vesicles or particles is delivered in to the skin by applying pulse leading to 
breakdown of the stratum corneum. Pressure medicated electroincorporation 
has been used to deliver leuprolide acetate micropheres into hairless mouse 
skin and human skin engrafted on immunodeficient nude mice. It has been 
shown that application of continuous low voltage resulted in a calcein flux 
with three orders of magnitude.
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   Besides, the modes compounds calcein, other drugs investigated for 
transdermal  delivery  by electroporation  includes;  metaprolol  flurbiprofen, 
cyclosporine, heparin, fenanyl and oligonucleotides67.
 SONOPHORESIS TECHNOLOGY68
    Ultra sound has been used to treat a wide range of clinical condition 
and to transport drugs to deeper tissues.  The movement of drugs through 
living perturbation is called Sonophoresis.  Ultra sound was applied with a 
sonicator (VCX-400 sonics and materials) operating at a frequency of 20 
KHz.  The sonicator were operated in the duty-cycle; that is pulsed mode 
(0.1s on and 0.9s off or 1s on and 9s off or 5s on and 5s off).  
     Ultra  sound  may  enhance  transdermal  drug  delivery  systems  by 
affecting the skin structure (through which enhanced diffusion may occur), 
by inducing concection or by a combination of both effects. Because, skin 
conductivity is an excellent indicator of the skin barrier properties.  
   The ultra sound application has resulted in modest  permeation of 
simple molecular.  It was reported that, low frequency ultrasound could be 
used  to  deliver  insulin  across  rabbit  skin  in  vivo,  resulting  in  increased 
plasma hormone levels and lowering of blood glucose. 
   Measurement of ultrasound intensity:   A commonly used calorimetric 
method was employed to calculate the power from the sonicator based on 
the change in the temperature of water exposed to the sonicator.  
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   Another method is aluminium foil  measurement.   In an attempt  to 
quantify  the  potential  of  the  sonicator  to  induce  transient  cavitations  in 
aluminium foil paper.  It was mounted onto the diffusion cell in a manner 
identical to that of the skin sonication was performed for 20s [0.1 on and0.9s 
off] and then aluminium foil was  remove from the cell. The number of pits 
on the foil was determined by visual inspection.  The pits represent physical 
evidence  of  the  effects  of  cavitations  bubble  formation  induced  by 
ultrasound.
MICROFABRICATED MICRONEEDLES AND MICROCHIPS 
TECHNOLOGY18
    The micro fabricated micro needles technology employs micro-sized 
needles made from silicon.  These micro needle arrays after insertion into 
the skin create conditions for transport of drug across the stratum corneum. 
The drug after crossing the stratum corneum diffuses rapidly through deeper 
tissue  and  taken  up  by  capillaries  for  systemic  administration.   Micro 
needles were made using the micro fabrication technology similar as that of 
making of integrated circuits.  The micro fabrication technology is simple 
for  cheap and mass production of micron sized structures.   For the drug 
delivery,  a  three-dimensional  array  of  sharp-tipped  micro  needles  with 
approximately 150micrometre, in lengths was fabricated.  Deep reactive ion 
etching technique is based on the black silicon method.  Each micro needle 
is about 1 micron in diameter or one hundredth of the diameters of a human 
hair. These needles can be seen only under a microscope.   A microprocessor 
and pump for delivering tiny amounts of the drug. 
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The microprocessor and pump automatically inject the right dosage of the 
drug.  The micro needles have extremely sharp tips with radius of curvature 
less than 1mm facilitating easy piercing into the skin. 
 1.5  SKIN  AS  A  SITE  FOR  TRANSDERMAL  DRUG  DELIVERY 
SYSTEMS
 STRUCTURE OF THE SKIN
    The  skin  consists  of  different  tissues  that  are  joined  to  perform 
specific functions. The thickness of the skin cover most of the body is 1-2 
mm thick.
   Structurally the skin consists of two principal parts. The superficial, 
thinner portion which is composed of epithelial tissue is the epidermis. The 
deeper, thicker, connective tissue part is the dermis. Deep to the hypodermis 
and not part of the skin is the subcutaneous layer. The hypodermis layer 
consists of areolar and adipose tissues. The sub cutaneous layer serves as a 
storage depot for fat and contains large blood vessels that supply the skin. 
This region also contains nerve endings called lamellated corpuses that are 
sensitive to pressure.
 Epidermis
   The epidermis is keratinized stratified squamous epithelium. It 
contains four principal types of cells, keratinocytes, melanocytes, langerhans 
cells and merkel-cells. About 90% of epidermal cells are keratinocytes 
which produce the protein keratin20
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       Epidermis consists of following layers:
o Stratum basale,
o Stratum spinosum,
o Stratum granulosum,
o Stratum lucidum,
o  Stratum  Corneum. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No.7 Structure of the Human Skin
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Stratum Basale:
    The deepest layer of the epidermis is the stratum basale, composed of 
a single row of cubical or columnar keratinocytes.
      Superficial to the stratum basale is the stratum spinosum where 8-10 
layers of polyhedral keratinocytes fit closely together.
Stratum Granulosum:
At the middle of the epidermis the stratum granulosum consists  of 
three to five layers of flattened keratinocytes that are undergoing apoptosis.
Stratum corneum:
The  stratum  corneum  consists  of  25-30  layers  of  dead,flat 
keratinocytes.  The  interior  of  the  cells  contains  mostly  densely  packed 
intermediate filaments and keratohyalien. Between the cells are lipids from 
lamellar granules that help to make this layer water-repellent. These cells are 
continuously shed and replaced by cells from the deeper strata. The stratum 
corneum  serves  as  an  effective  water-repellent  barrier  and  also  protects 
against injury and microbes.  Constant exposure of skin to friction stimulates 
the formation of a callus an abnormal thickening of the epidermis21.
 ROUTES OF PENETRATION
When  a  molecule  reaches  intact  skin  it  contacts  cellular  debris, 
microorganisms, sebum, and other materials.  The diffusing then has three 
potential entry routes to the viable tissue- through the hair follicles with their 
associated sebaceous glands, via the sweat ducts, or across the continuous 
stratum corneum between these  appendages.  We can summarize  relevant 
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features arriving at a general conclusion27
 Sebum and surface material
   The layer of sebum mixed with sweat, bacteria, and dead cells is this 
(0.4 – 10 µm), irregular, and discontinuous: it hardly affects percutaneous 
absorption.
 Skin appendages
   Their fractional  area available for absorption is small  (about 0.1%) 
and this route usually cannot contribute appreciably to the steady state flux. 
However, the route may be important  for  ions and large polar molecules 
which cross-intact stratum corneum with difficulty.  Diseases, which disturb 
the horny layer, such as eczema and exfoliate dermatitis, allow easy access.
    Skin appendages may act as shunts, important at short times prior to 
steady  state  diffusion,  e.g.  in  bioassays  which  use  pharmacological 
reactions.   Thus  minute  concentrations  of  nicotinates  or  corticosteroids 
penetration rapidly down the shunt route may trigger erythema or blanching.
 
Epidermal route
   The epidermal layers (particularly the epidermis) may metabolize and 
inactivate a drug, or activate a prodrug.  The dermal papillary layer contains 
so many capillaries that the average residence time of a drug in the dermis 
may  only  be  about  a  minute.  Usually,  the  deeper  dermal  layers  do  not 
influence  percutaneous  absorption.  However,  the  dermis  may  bind  a 
hormone  such  as  testosterone,  decreasing  its  systemic  removal.  If  the 
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penetrant is very lipophililc, it crosses the horny layer to meet an aqueous 
phase  in  which it  is  poorly  soluble.  The  chemical  potential  immediately 
below the barrier may then become high, approaching that in the barrier. 
The potential gradient (stratum corneum to viable tissue) falls, together with 
the flux. The rate-determining step in percutaneous absorption the becomes 
barrier clearance not barrier penetration.
    Within the stratum corneum, molecules penetrate either intercellular 
or transcellularly. Electron micrographs of intercellular material suggest a 
segregation  of  lipid between protein filaments.  In  hydrated  tissues,  these 
lipid  and  polar  regions  would  provide  parallel  pathways  for  diffusion. 
Molecules would portion into and diffuse through, either network according 
to their  polarities.  The intercellular  route  is  rich in  neutral  lipid and this 
pathway may be more important in percutaneous absorption than previously 
thought.
    Topically  applied  agents  such  as  steroids,  hexachlorophane, 
griseofulvin, sodium fusidate and fusidic acid may form a depot or reservoir 
by binding within the stratum corneum.
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  MECHANISM OF SKIN PERMEATION
      A systematically active drug that will reach a target tissue  from the 
site  of  drug  administration  of  the  skin  surface  must  posses  some 
physicochemical properties that are capable of facilitating the absorption of 
drug through the stratum corneum the penetration of drug through viable 
epidermis and also uptake of the drug by capillary network in the dermal 
papillary layer. The sequence of transdermal permeation of drug is shown.
  The rate of the permeation, dq/dt across the skin tissues can be expressed 
mathematically by the following relationship.
                                            dq/dt = Ps[Cd-Cr].
Where 
Cd and Cr, respectively the concentration of a skin penetrant in the 
donor compartment (e.g. Body),
 Ps is the overall permeability coefficient of the skin.
 
                                         Ps = Ks Dss/hs.                           (1)
 Where 
Ks  is  the  partition-coefficient  for  the  interfacial  partitioning  of  a 
penetrant  molecule  from  the  solution  of  medium  or  a  transdermal  drug 
delivery system on to  a stratum corneum;  
Dss  is  the  apparent  diffusity  for  the  steady  state  diffusion  of  the 
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penetrant molecule through a thickness of skin tissues.3
       Analysis of (eq-1) suggests that to achieve a constant rate of drug 
permeation one needs to maintain the drug concentration on the surface of 
stratum corneum      (Cd)    consistency and substantially greater than the 
drug concentration in the body (Cr), 
         i.e.., Cd>Cr;
Under such a condition eq.1 can be reduced to
                                             dq/dt =  PsCd
 The  rate  of  skin  permeation   dq/dt  becomes  a  constant,  if  the 
magnitude of   Cd remains fairly constant   throughout the course of skin 
permeation to maintain  Cd at a rate (Rd) that is either constant or always 
greater than the rate of skin update (Ra),  i.e. Rd> Ra. By making Rd greater 
than Ra the drug concentration on the skin surface (Cd) is maintained at a 
level equal to or greater than the equilibrium (or saturation) solubility of the 
drug in the stratum corneum (Cse).ie., Cd.C>Cse and a maximum rate of skin 
permeation
                                              (dq/dt)m = PsCse
    The  other  mechanism  of  permeation  involves  diffusion  through 
shunts  particularly  those  offered  by the relatively  widely  distributed  hair 
follicles and exocrine glands.   Typically one square centimeter  of human 
skin  yields  10 hair  follicles,  15  sebaceous  glands  and 100 sweat  glands. 
However  the  appendages  provide  a  small  fractional  surface  area  of 
approximately 0.1% of the total skin area.
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   Recent studies indicate the importance of appending in percutaneous 
absorption. The appendages route may be more significant for ions and large 
polar molecules, which slowly permeates across the bulk of the intact horny 
layer. The two potential micro pathways serve the stratum corneum through 
the  transcellular and intercellular route. 
   The principal pathway taken by the penetrant is decided mainly by 
diffusant’s partition coefficient . Most of the diffusant’s permeate by both 
the routes. The intercellular pathway is considered to provide the principal 
route and the major barrier to the permeation of the drugs.
1.6  FACTORS AFFECTING TRANSDERMAL PERMEABILITY
    Physiological and pathological conditions of the skin .28
1. Skin condition: 
• Intact  skin  prevents  penetration.  When  the  skin  is 
exposed to  mustard  gas,  hydrogen sulphide  gas,  acids, 
alkalies  or  ultra  violet  radiation,  skin  turns  to  porous 
form which will lead to enhanced drug penetration. Mild 
burns will increase the penetration whereas severe burns 
retard.
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2. Skin hydration: 
• Hydration results from water diffusing from underlying 
epidermal layers or from perspiration accumulation after 
application of  an occlusive  vehicle  or  covering on the 
surface.
• Under occlusive conditions densely and closely packed 
cells of the skin are opened up and increase its porosity. 
Occlusion  also  reduces  the  “irreversible”  binding 
capacity of stratum corneum. When the skin undergoes 
hydration, its resistance and capacitance may change. As 
the  time  of  hydration  increases  the  low  frequency 
impedance  of  the  excised  skin  decreases  with  time.  A 
much less activation energy is required to diffuse through 
hydrated skin.
3. Skin Age: 
• Fetal and infant skin appears more permeable than adult 
skin. The stratum corneum of preterm infants is not well 
developed  and  as  such  provides  little  barrier  to  the 
ingress of substances. So this route of delivery is possible 
for  neonatal  therapy,  when difficulty  is  encountered in 
oral or  
4. Increased blood flow: 
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• Due to increased blood flow, a concentration gradient is 
established which will promote drug absorption.
      5. Skin Temperature:
• Raising skin temperature results in an increase in the rate 
of skin permeation. This may be due to thermal energy 
required  differently  solubility  of  drug  in  skin  tissues. 
Increased vasodilatation of skin vessels.
6.Regional skin sites: 
 Difference in the nature and thickness of the barrier layer 
of the skin causes variation in permeability.
7. Cutaneous drug metabolism: 
 Catabolic enzymes present in the viable epidermis may 
render a drug inactive by metabolism and thus affect the 
topical bioavailability of the drug.
8.Species variation:
• Human and animals display wide differences in physical 
characteristics such as the number of appendage openings 
per unit area and the thickness of the stratum corneum. 
The average permeability order is Monkey > Dog >Goat 
> Rat > Guinea pig > Mouse > Human skin.
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Physicochemical properties of the penetrant molecules29.
I. Partition  coefficient:  A  lipid/water  partition  coefficient  of  1  or 
greater  is  generally  required  for  optimal  transdermal  permeability. 
The  partition  coefficient  of  a  drug  molecule  may  be  altered  by 
chemical  modification of its  functional  groups.  Membrane partition 
coefficient  increases  exponentially  as  the  length  of  the  lipophillic 
alkyl chain increases.
II. pH conditions : Application of solutions whose pH values are very 
high or very low can be destructive to the skin. With moderate pH 
values, the flux of ionizable drugs can be affected by changes in pH 
that  alter  the  ratio  of  charged  to  uncharged  species  and  their 
transdermal permeability.
III. Drug concentration: The amount of drug percutaneously absorbed 
per unit surface area over time interval increase as the concentration 
of the drug in the vehicle is increased.
IV. Molecular characteristics of drug: An inverse relationship appears 
to  exist  between  absorption  rate  and  molecular  weight.  Small 
molecules penetrate more rapidly than large molecules.  Drugs with 
molecular weights of upto 500 Dalton can penetrate well.  Drugs with 
molecular weights above 500 Dalton can be delivered transversally by 
iontophoresis.
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Physicochemical properties of drug delivery systems30. 
I. Vehicle:  Vehicles  serve  as  drug  carriers.  Lipophillic  solvents 
facilitate penetration.  The absorption of water-soluble and lipid 
soluble substances from terpene and terpene derivatives was better 
than  from alcoholic  solutions.  Solubility  of  drug  in  the  vehicle 
determines the rate. 
II. Composition of drug delivery systems: It affects not only the rate 
of drug release but also the permeability of stratum corneum by 
means  of  hydration  mixing  with  skin  lipids  or  other  sorption 
promoting effects.
III. Enhancement  of  transdermal  permeation:  Transdermal 
permeation  can  be  increased  by  including  some  penetrates, 
sorption promoters etc. Organic solvents like Dimethyl acetamide, 
dimethyl  formamide,  dimethyl  sulfoxide,  ethylene  glycol, 
propylene glycol and polyethylene glycol.
IV. Surfactants:  Anionic  surfactants  are  the  most  effective.  E.g. 
Sodium  lauryl  sulphate.  Chemical  like  Azone  also  promote 
absorption.
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1.7 POLYMERS OF TRANSDERMAL DELIVERY SYSTEM
 POLYMERS:
              The polymer controls the release of the drug from the devices. The 
following  criteria  should  be  satisfied  for  a  polymer  to  be  used  in  a 
transdermal system..31
1. Drug solubility and diffusivity in the polymer.
2. The  desired  drug  loading  and  its  effect  on  polymer 
integrity.
3. Compatibility  of  the  polymer  with  necessary 
excepients,  such  as  solvents  and  skin  permeation 
enhancer of the drug.
4. Skin  compatibility:  The  effect  of  moisture  occluded 
under the polymer formulation.
5. Mechanical  properties:  Softness,  Flexibility 
Compatibility to skin and mechanical integrity.
6. Ease of fabrication.
7. Toxicity  and  purity  i.e.,  compliance  with  safety 
requirements of the FDA.
8. Cost and availability.
         It is rare to find a commercial polymer that satisfies all the above 
criteria  for  polymer  selection.  Hence  various  techniques  have  been 
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employed to modify the polymer properties and thus drug release rates.
Cross-linked polymers : 
The higher the degree of cross-linking the more dense the polymer 
and slower the diffusion of drug molecule through the matrix cross-linking 
may be achieved chemically using cross-linking agent or by irradiation. This 
approached has been applied to the preparation of the Nitrodisc system.
Polymer blend: 
    The  blended  polymer  combines  the  advantages  of  individual 
polymers.   The  potential  advantages  include  easy  fabrication  of  devices 
manipulation of drug loading and other device properties such as hydration, 
degradation and mechanical strength.
Plasticizers: 
      Plasticizers are used to reduce the stiffness of the polymer backbone 
there by increasing the diffusion characteristics of the dug. In selection of 
plasticizer care must be taken to select a material, which is biocompatible. 
Commonly used plasticizers are polyethylene glycol, polypropylene glycol, 
glycerol, and dibutylphthalate and dioctyl phthalate32.
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COMMONLY USED POLYMERS IN TRANSDERMAL FILM
Poly-isobutylene
   Poly-isobutylene  (PIB)  is  a  highly  paraffinic,  non-polar  and 
amorphous  hydrocarbon  polymer  composed  of  essentially  straight  chain 
macromolecules.  Physical  properties  of  PIB  change  gradually  with 
increasing molecular weight, the lowest molecular weight polymers being 
viscous liquids. With increase in molecular weight the liquids are become 
more viscous,  then change to balsam like sticky masses and finally form 
electrometric solids PIB is soluble in hydrocarbon solvents and insoluble  in 
polar solvents,  PIB exhibits excellent low-transition temperature flexibility 
and oxidative stability.
Polyvinylpyrolidone/Polyvinyl alcohol
   Polyvinylpyrolidone  (PVP)  is  a  white,  odorless  and  hygroscopic 
powder. It is available in different viscosity grades, identified by K value.  It 
is soluble in water and in many organic solvents. Polyvinyl alcohol (PVA) is 
a cream coloured granular powder and is prepared from Polyvinyl acetates. 
PVA is available in different grades and the viscosity is directly proportional 
to  its  molecular  weight.  Both  PVA&PVP  are  non-toxic  to  skin  and 
incompatible with inorganic salts.
Ethylene vinyl acetate (EVA) copolymers
   EVA’S are ideally suited for preparation of molecular diffusion type 
membranes because their permeability properties can be varied over a wide 
range by changing vinyl acetate content. The stiffness, tensile strength and 
softening  point  decrease  with  increasing  vinyl  acetate  content  while  the 
permeability and toughness increase. EVA has been shown to be chemically 
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stable, non-toxic and biocompatible. 
Vinyl chloride polymers and copolymers
   Vinyl  chloride,  polymers  and copolymers  useful  for  drug/polymers 
matrix preparation include homopolymers vinyl chloride. CH2 = CH-Cl2 and 
copolymers having a high vinyl chloride content. PVC needs plasticization 
in  order  to  form a  soft  and  flexible  film suitable  for  transdermal  patch 
formulation.   The  commonly  used  plasticizers  are  dioctyl  phthalate, 
epoxidized Soya bean oil and Citric acid esters.
Cellulose derivatives
   Many  cellulose  derivatives  are  employed  for  transdermal  drug 
delivery  like  ethyl  cellulose,  methylcellulose,  cellulose  acetate  phthalate, 
cellulose  acetate  butyrate,  hydroxyl  propyl  methyl  cellulose,  carboxyl 
methyl  cellulose  sodium  they  are  mostly  used  in  the  combination  with 
hydrophilic polymers like PVP, PEG etc.,.
1.8 SELECTION OF DRUG CANDIDATES FOR TRANSDERMAL 
DELIVERY
The choice  of  drugs  to  be  delivered  is  almost  a  difficult  one,  and 
careful  consideration  should  be  given  for  selection  of  suitable  drug 
molecule. The following are some of the desirable properties of a drug for 
transdermal delivery.
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Physico-chemical properties of the drug:
1. The drug should   have  a  molecular  weight  of  less  than 500 
Daltons
2. The  drug  should  possess  balanced  lipophilic,  hydrophilic 
characteristics and also has reasonable solubility in both lipid 
and aqueous phases. The logP value should be in the range   1-3
3. The melting point should be less than 200 0 C
4. Saturated aqueous solutions of the drug should have pH value 
between 5 and 9.
5. Hydrogen bonding groups should be less than or equal to 2.
Biological properties of drug
1. The biological half-life (t 1/2) should be less than 5-6 hours.
2. The drug should be potent with a daily systemic dose of  less  than 
20mg.
3. The drug should not stimulate an immune reaction in the skin.
4.  The drug must not induce a cutaneous irritant or allergic response. 
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2. Literature Review
• J.Y.Park  et.  al.,71 Studied  comparative  pharmacokinetic  and 
pharmacodynamic  characteristics  of  amlodipine  besylate  and 
amlodiple  nicotinate in healthy subject  and the results shows mean 
ratio for AUC0-α and Cmax fell within the predetermined equivalent 
range of 80-125% pharmacodynamics profiles including systolic and 
diastolic  blood  pressures  and  pulses  rates  exhibited  no  significant 
differences between the two formulations
• Paul  W.Stott.  et  al.,72  Done  mechanistic  study  into  the  enhanced 
transdermal    permeation  of a model β-blocker, propranolol, by fatty 
acid:  a  melting  point  depression  effect  and  found  that  the  binary 
mixture  of  propranolol  and fatty  acid,  the  addition compounds  are 
formed by interaction between the carbonyl group of the β-blocker, to 
form a  salt.  The  oppositely  charged  species  of  the  salt  have  been 
shown to permeate the human epidermal membrane by an ion – pair 
mechanism.  This  is  in  agreement  with  the  work  by  Green  and 
Hadgraft (1987) which suggested the formation of ion-pairs between 
propranolol and fatty acids. Where the process was driven by a pH 
gradient.
• D. Monti et.al.,73 Conducted study on the comparison of the effect of 
ultra  sound  (US)  and  of  chemical  enhancers  on  transdermal 
permeation of caffeine(CAF) and morphine through hairless  mouse 
skin  in  vitro,  and  found  that  CAF  confirm  greater  effect  of  low-
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frequency US on skin permeation in vitro. The comparison of US and 
chemical  enhancement  indicates  a  slight  superiority  of  the 
combination oleyl  alcohol (OA) / propylene glycol (PG) over low – 
frequency US. Concerning morphine (MOR), significantly increased 
transdermal fluxes were produced by both low frequency US and by 
OA in combination with PG.
• Rajagopal  K.  et.  al.,74 Formulate  and  evaluate  a  matrix  type 
transdermal patches of nimesulide by using different polymers alone 
or in combination, dibutyl phthalate as the plasticizer and aluminum 
foils  as  the  backing  membrane.  The  studies  showed  that  (2.2) 
hydroxyl propyl methyl cellulose (HPMC) and ethyl cellulose (EC) 
combination  may  be  the  suitable  polymer  combination  for  the 
development of transdermal drug delivery system of nimesulide
• Jawahar  N.  et.al.,10 Prepare  and  evaluate  verapamil  hydrochloride 
transdermal  films  and  study  the  effect  of  different  formulation 
variables.  The  drug  diffusion  through  the  films  followed  a  pattern 
close to zero order type. The drug release profile was decreased with 
increased polymer concentration and film thickness.
• L.M.A.  Nolan  et.al.,75 Studies  Iontophoretic  and  chemical 
enhancement of drug delivery part I: across artificial membranes and 
reported that the delivery of salbutamol from the fatty acid containing 
systems  was  substantially  enhanced  by  iontophoresis  and  the  rates 
were shown to be approximately proportional to the assisting currents. 
The data clearly indicates the iontophoretic process to be significantly 
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less efficient in the presence by buffer lons but with the iontophoretic 
delivery rates being enhanced by the presence of a fatty acid.
• M.B.Blanco.et.al.,76 Transdermal application of bupivacaine – loaded 
poly (acrylamide (A)- CO- monomethyl itaconate ) hydrogels found 
the skin flux of the drug was between 90 ±  5 and 16 ±  7 mcg/ cm2 /h 
depending on the amount of bupivacaine included in the gel and the 
gel composition. Skin flux increases with the drug load of the gels. 
Furthermore as more MMI in the gel slower skin flux of the drug due 
to bupivacaine gel interactions.
• A.Nokhodchi. et. al., 77 Studies the enhancement effect of surfactants 
on the penetration of lorazepam through rat skin. And concluded that 
the  increase  in  flux  at  low  enhancer  concentrations  is  normally 
attributed to the ability of the surfactant molecules to penetrate the 
skin and increase its permeatility. Reduction in the rate of transport of 
the drug present in enhancer system beyond 1% w/w is attributed to 
the  ability  of  the  surfactant  molecules  to  form  micelles  and  us 
normally  observed  only  if  interaction  between  micelle  & the  drug 
occurs.
• Xiaohong Qi et.. al., 78 Studies convolution method to predict drug 
concentration  profiles  of  2,3,5,6-tetra  –  methylpyrazine  following 
transdermal  application in  rabbit  from the  in-vitro  skin  permeation 
data and found that in – vitro skin permeation tests could be useful to 
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predict  in  vivo  drug  absorption  profiles  following  transdermal 
application.
• P.Rama  Rao.  et.al.,  79  Provide  comparative  in-vivo  evaluation  of 
propranolol hydrochloride after oral and transdermal administration in 
rabbits. The PK parameters such as maximum plasma concentration 
(Cmax),  tmax,  MRT  Mean  residence  time)  and  AUC0-α were 
significantly (P< 0.01) different following transdermal administration 
compared to oral administration. The t1/2 of transdermally delivered 
PPN was found to be similar to that following oral administration. But 
sustained  activity  was  observed  over  a  period  of  24hrs  after 
transdermal  administration  compared  to  oral.  The  relative 
bioavailability of PPN was increased about fivefold to six fold after 
transdermal compare to oral.
• Sandip B. Tiwari. et.al.,  80 Done investigation into the potential of 
iontophoresis facilitated delivery of ketorolac using rat skin. Results 
found that pretreatment of the skin with D-limonene in ethanol or D-
limonene  in  ethanol  +  ultra  sound  significantly  enhanced  the 
iontophoretic flux of the drug in comparision to passive flux with or 
without  pretreatment.  Trimodality  treatment  comprising  of 
pretreatment with D-limonene in ethanol+ultrasound in combination 
followed by iontophoresis was found to be most potent for enhancing 
the rate of permeation of ketorolac
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• Michal  A.Ashburn.  et.al., 81 Work  on  pharmacokinetics  of 
transdermal Fentanyl delivered with and without controlled heat and 
there  results  suggest  controlled heat  might  be used to  significantly 
shorten  the  time  needed  to  reach  clinically  important  fentanyl 
concentrations,  controlled  heat  might  be  useful  to  produce  rapid 
increase  in  serum  concentrations  for  the  rapid  treatment  of 
breakthrough pain.
• Jagdish  singh.et.al.,82  Done  work  on  electronically  facilitated 
transdermal  delivery  of  human  parathyroid  hormone  (1-34)  using 
porcine skin. The flux of hPTH (1-34) with the electroporation pulses 
of 100 and 300V followed by lontophoresis at 0.2mA/cm2 was 10 – 
and  5  –fold  higher  respectively,  in  comparison  to  the  flux  with 
corresponding pulses alone.
• Franziska  Grafe,et.al.,83 Work  on  carrier  mediated  transport  of 
clonidine  in  human  kerationocytes  to  characterize  transport  of 
clonidine  into  human  keratinocytes  to  characterize  transport  of 
clonidine  into  human  keratinocytes  and  conclude  that  clonidine  us 
transported  into  keratinocytes  in  a  pH  –  dependent  manner  by  a 
saturable  uptake  system  different  from  the  keratinocyte  choline 
transporter
• P.N.Kotiyan.  et.al.,84 Studies  electron  bean   irradiation;  a  novel 
technology for the development of transdermal system of lsosorbide 
dinitrate  (ISDN)  dissolving  in  2-ethylhexylacrylate  (EHA)-acrylic 
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acid (AA) and solution irradiated on a backing membrane at different 
doses  to  get  transdermal  patches.  The  ISDN-EHA-AA  system 
developed  at  an  irradiation  dose  of  50KGY showed  a  higher  skin 
permeation  profile  as  compared  to  an  internationally  marketed 
transdermal matrix system of ISDN.
• Elvira  Escribans.  et.  al., 85  Done  assessment  of  diclofenaec 
permeation  with  different  formulation  using  human  skin(0.4mm 
thick)from plastic  surgery as a membrane.  The results  suggest  that 
topical  delivery  of  sodium diclofenac  with  an  absorption  enhancer 
such as a mixture of oleic acid and d-limonene may be an effective 
medication for both dermal and subdermal  Injuries
• Jorg  kreuter  et.al.,86 Carry  studies  on  crystallization  of  estradiol 
containing TDDS determined by isothermal microcalorimetry X-ray 
diffraction and optical microscopy as it is still a problem to achieve a 
stable and prolonged constant drug release, to attain high permeation 
rates across the skin, the concentrations of the drug dissolved have to 
be  high  and  often  create  supersaturated,  thermodynamically 
metastable  or  unstable  systems  that  possess  a  high  tendency  to 
crystallise.
• M.Jayne Lawrence et.al., 87 Done work on formulation of electrically 
conducting micro emulsion – based organogels. (MBG). From work 
conclude that  MBG not formed with non-ionic surfactant  alone,  or 
when  used  in  combination  with  another  non-ionic  surfactant 
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(regardless of oil  used). Which is due to inadequate level  of water 
available for by hydration of the surfactant head group.
• Akirayamanoto  et.al.,88 Enhanced  transdermal  delivery  of 
phenylalanyl-glycine  by  chemical  modification  with  various  fatty 
acids shows the results that the stability and permeability of Phe-Gly 
were improved by chemical modification with improved by chemical 
modification with fatty acids and this enchanced permeability of Phe-
Gly by the acylation may be attributed to the protection of Phe –Gly 
from the enzymatic degradation in the skin and the increase in the 
partition of Phe-Gly to the stratum corneum.
• K.C. sung, et.al., 89 assess the effect of electro oration on transdermal 
permeation of nalbuphine (NA) and its prodrug. Study demonstrated 
that  electroporation enhance and control  transdermal  permeation of 
NA  and  its  prodrugs.  The  results  also  indicated  that  the 
physicochemical  properties  of  prodrug  has  significant  effects  on 
kinetics  as  well  as  mechanisms  of  transdermal  permeation  by 
electroporation. 
• Ramesh  panchagnula  et.al.,90 work  on  transdermal  delivery  of 
zidovudine effect of vehicles  on permeation across rat skin and their 
mechanism of action, to assess to effect of various solvent systems 
containing water, ethanol, propylene glycol (PG). Studies support that 
among all the solvent combinations, highest flux and short lag time 
were archived with ethanol at 66.6% in water and hence is a suitable 
vehicle for transdermal delivery of AZT.
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3. Aim and Objective 
Objective of this study
Cardiovascular drugs have relatively low therapeutic indices, which 
place  responsibility  on  the  dosage  forms  for  maintaining  the  drug blood 
level within narrow limit .Conventional dosage forms suffer from variations 
in the absorption and thus leading to wide fluctuation in the plasma drug 
concentration.
Amlodipine  Besylate,  is  an  antihypertensive  drug,  having  calcium 
channel blocking activity is therapeutically active even at very low doses. 
E.g.: 5-10mg/day    which is one of the essential requirements of a drug 
candidate for use in transdermal delivery systems.
It also has other suitable properties which include.
1. Low molecular weight.
2. High lipid solubility 
3. Extensive first pass metabolism etc.
Transdermal  film  prepared  by  various  polymers  can  exhibit  good 
controlled release properties. So, an attempt is done to formulate transdermal 
film containing Amlodipine Besylate for achieving following goals.
1. To produce steady state plasma concentration 
2. To improve stability of Amlodipine in vivo
3. To reduce adverse effect. 
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4. Plan of Work
1. Identification of drug by spectrophotometric method (IR and UV).
2. Determination  of  the,  partition  coefficient  and  melting  point  of 
Amlodipine.
3. Determination of the drug polymer interaction study between the drug 
(Amlodipine Besylate) and the polymer (HPMC) through differential 
Scanning calorimetry (DSC)
4. Study  on  the  extent  of  in  vitro  permeation  of  Amlodipine  from 
Transdermal device in the presence of penetration enhancers.
5. Study on the in  vivo release pattern using rabbit.
6. To study the skin irritation of transdermal film using rabbit. 
7. Stability Studies
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                             5. DRUG PROFILE OF AMILODIPINE BESYLATE
5.1 DRUG   PROFILE
Drug Name - Amlodipine besylate
Classification - calcium channel blocker
Synonym - Amlodipine besylate
Chemical structure
Chemical Name      - 3-Ethyl 5– Methyl (4R, S) -2- [(2-Amino 
Ethoxy) Methyl), 4-(2-Chlorophenyl)–6-
Methyl–1,4–dihydropyridine–3,5 
dicarboxylate benzene Sulphonate
 Molecular weight            - 567.1
Molecular formula            -
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Description
Colour -  white crystalline powder
Partition coefficient(log P) -3.00
Dissociation Constant 
(PKa) at 25 0 C      - 8.6
Odour - odourless
Solubility - slightly soluble in water
                                         -         Sparingly soluble in ethanol
                               -           Freely soluble in methanol
Melting point -        178 -179 0 C                                    
Optical rotation - Racemic mixture
  
CLINICAL PHARMACOLOGY 12, 16
Amlodipine  Besylate is a Dihydro pyridine derivative which is the 
most  potent  Ca2+ Channel  Blockers.  Bind  to  specific  sites  on  the  alpha1 
subunit, all restricting Ca2+ entry
cAMP – phospho diesterase resulting in raised smooth muscle cAMP 
showing smooth muscle  relaxant action. 
Released  endothelial  nitrous  oxide  may  exert  anti  atherosclerotic 
action.
Amlodipine inhibits the movement of Calcium Ions (Ca2+) across the 
cell membrane into vascular smooth and myocytes. Action is greater in the 
arterial resistant vessels causing peripheral vasodilatation and reduction in 
after load. Action on the myocardium is considerably less. In angina patient 
reduction of after load reduces myocardial oxygen requirement. 
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Amlodipine produces vasodilatation resulting in a reduction of supine 
and standing blood pressure.  Amlodipine does not change sinoatrial (SA) 
nodal  function  or  atrioventricular  (AV)  conduction  in  intact  animals  or 
humans. The decrease in blood pressure is not accompanied by a significant 
change in heart rate or plasma catecholamine levels with chronic dosing. 
Vasodilatations also increase the oxygen available to the heart in patients 
with coronary artery spasm and blunt coronary vaso constriction. 
PHARMACOKINETICS:
Absorption/ Distribution:
Amlodipine  is  almost  completely  well  absorbed  following  oral 
administration with no effect of food. Bioavailability range is 45 -60% Due 
to  a  significant  degree  of  first  pass  metabolism.  Following  oral 
administration, . Time to peak plasma levels occur after 6 -12 hours. 
Amlodipine,  plasma  protein  binding  is  97.5  %  having  volume  of 
distribution around 20 L\ Kg. Time to steady state is 7 To 8 days. A normal 
serum level of Amlodipine may fall in the range 3-11 ng/ml. Amlodipine 
Crosses the Blood Brain Barrier, Placenta & is excreted in Breast Milk. 
Metabolism/ Excretion: 
Amlodipine is extensively metabolized in the liver, with 10 % of the 
parent  compound  and  60%  of  the  metabolites  excreted  in  the  urine.  In 
patients with hepatic dysfunction, decreased clearance of Amlodipine may 
increase the area under the plasma concentration curve by 40 % - 60 % & 
dosage  reduction  may  be  required.  5%  dose  of  Amoldipine  recovered 
unchanged through urine.
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Dosage 
Adults: 5 – 10mg once a day 
Elderly patient should start with 2-5mg one day & the dose built up as 
required.
Therapeutic uses:
Amlodipine is used in the treatment for:
 Stable and Prinzmetals angina, 
Heart failure,
 Hypertension.
5.2 Excipients profiles
Hydroxyl propyl methyl cellulose
  
 Non-proprietary Name Hypromellose
Hydroxyl propyl methylcellulose
  Functional category Suspending agent 
Coating agents
Tablet binder
Film former
  Synonyms Methyl hydroxyl propyl cellulose
Propylene glycol, ether cellulose
Hydroxyl propyl methyl cellulose
 Chemical Name Cellulose 2- hydroxyl propyl methyl ether  
cellulose,  hydroxyl  propyl  methyl 
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ether.
 Typical properties
Density 0.341 gm/cm3
Solubility Soluble in cold water forming viscous colloidal 
solution. Insoluble in alcohol, ether and 
chloroform.
 Grade HPMC K 100 M
HPMC K 4 M
HPMC K 15M 
HPMC k100 LVP 
 Viscosity HPMC K 100 M    - 8000 to 120 000 m pas
              HPMC K 4 M       - 3000 to 5600     m pas
Application of HPMC in Pharmaceutical Formulation
Film former in tablets film coating. Lower viscosity grades are used in 
aqueous film coating.  Higher  viscosity  grades may be used to retard the 
release  of  drugs  from a  matrix  a  levels  of  10  -  80  %w/w in  tablet  and 
capsule. Depending up on the viscosity grade, concentration of 2 - 20% w/w 
are used for film forming solution to film coat tablet. Lower viscosity grade 
are used in aqueous film coating solution, while higher viscosity grades are 
used with organic solvent.
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6.MATERIALS AND METHODS
6.1 Equipments 
UV- Visible spectro photometer
Shimadzu – 1700 model.
Open tubular cell
Magnetic stirrer
PH meter
Differential scanning calorimeter : Perkin  Elmer, DSC-7
Fourier Transform Infrared : Perkin Elmer. .
6.2 List of reagents
0.1 N Hydrochloric acid 
8.5 ml of Concentrated Hydrochloric acid is dissolved in 1000 ml of 
distilled water.
6.3 Materials 
Amlodipine  Besylate  BP-  Standard  drug  Supplied  by  Orchid 
Pharmaceuticals Ltd, Chennai.
Hydroxypropyl methyl Cellulose – Supplied by S.D. Fine chemicals, 
Bombay.
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Methanol  –  (Analytical  grade)  supplied  by  Allied  chemicals 
corporation, Vadodara.
Dimethyl sulphoxides (DMSO) 
supplied by Suvidhinath Laboratories, Baroda.
6.4 Methods
Preformulation Studies
1. IR Determination
IR determination was carried out by Perkin Elmer Infra-Red
 Spectrophotometer using KBr Pellet technique 69,70
2. Melting point determination 
Melting point of pure Amlodipine Besylate was carried out by open 
capillary tube method. 
3. Differential scanning calorimetry DSC, 64  70
The excipient  induced modification  in  the thermal  behaviour,  were 
able to correlate long - term stability behaviour simply with the changes in 
thermal  features  characteristics  of  the  drug  alone.  Compatibility  and 
incompatibilities in DSC is concluded by elimination of endothermic peaks 
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(s), appearance of new peaks (s), change in peak shape and its onset, peak 
temperature / melting point and relative peak area or enthalpy.
Method 
The DSC analysis of each sample under the analogues conditions of 
temperature range ( 50 – 550C), heating rate (200 min-1), chart speed 1cm-1 
under nitrogen atmosphere, with alumina as reference material, were carried 
out by using Perkin - Elmer DSC -7 analyser.
In order to avoid the need for normalization of enthalpy change of 
account of great variation in sample weight, care should be taken to conduct 
DSC analysis accurately. Weight 5 mg or very close to 5 mg portions of the 
drug, as well as each excipient and transdermal film (2-8mg) equivalent to 
5mg of the drug. This would help not only to evaluate data analysis in terms 
of enthalpy change (loss / gain) associated with the peak of interest but also 
provide the gross idea about the possibility of interaction simply from visual 
comparison of the curves relevant to the individual excipient 
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4. Determination of partition efficient (P) 51,57
Partition coefficient is the ratio of concentration of drug in n-octanol 
to the concentration of drug in water. The concentration determined by using 
UV-spectrophotometer.
The  intrinsic  partition  coefficient  (P1)  may  be  more  appropriate 
parameter  to  measure  the  partition  coefficient  of  the  non-ionized 
compound. So, P1 was calculated using formula.
P1 = P [antilog [Pk – PH] +1
6.5 Standard Curve for Amlodipine61
Standard curve of Amlodipine were drawn in 0.1NHCl using
 UV- Visible spectrophotometer.
Procedure for the Preparation of Standard Curve:-
Amlodipine  Besylate  50mg  each,  were  accurately  weighed  and 
dissolved separately in 50ml of methanol.  Five ml of the above solutions 
diluted separately to standard stock solution of 100 mcg/ml eight dilutions 
ranging 5-40 mcg/ml made. The absorbance of each sample was measured 
using  UV-visible  spectrophotometer.  0.1  N HCl  as  blank.The  calibration 
curve  was  drain  by  plotting  concentration  Vs  and  absorbance  to  obtain 
standard calibration curve. The results were shown in table and figure. 
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Table No.2 Standard Curve for Amlodipine
Concentration (mcg/ml) Absorbance (365nm)
5 0.076
10 0.150
15 0.179
20 0.258
25 0.289
30 0.353
35 0.425
40 0.468
r-0.9968
a-0.0244
b-0.0111
Standard Curve for Amlodipine
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6.6   procedure for fabrication of transdermal film
Procedure for fabrication of transdermal. Medicated monolithic films: 
Transdermal films were prepared by the film casting method of specially 
designed  glass  molds  with  plastic  transparent  sheets.  Different  ratio  of 
polymer.  1:4(F2),  1:6(F3)  and  1:8(F4)  (Drug:  HPMC)  were  used  for 
preparation of films. Varying ratio of polymer dissolved in water. Then drug 
which dissolved in small quantity of methanol was incorporated in polymer 
solution  obtained  by stirring  with  glass  rod  for  10  min.  The  penetration 
enhancer (Dimethyl sulphoxide) is added to Drug- polymer solution. The 
solution is poured on petridish using rod. The rate of evaporation of solvent 
was controlled by inverting cup funnel. After 24 hrs, the dried films were out 
and stored in desiccator between sheets of paper.
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Table No.3 Formula for TDDS
Formulation Drug (mg) HPMC
(mg)
DMSO
(ml)
Solvent (water) 
(ml)
F1 25 50 2ml Upto 7 ml
F2 25 100 2ml Upto 7 ml
F3 25 150 2ml Upto 7 ml
F4 25 200 2ml Upto 7 ml
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6.7 EVALUATION OF TRANSDERMAL DRUG DELIVERY 
SYSTEM
Permeation Studies 10,49
The  in  vitro  permeation  studies  were  carried  out  using  Dialysis 
membrane.  The membrane  was prepared using following procedure.  The 
membrane is cut into appropriate size & socked in liquid glycerol for 24 
hours for permeable characteristics. 
The permeation study was conducted using open tubular cell in the 
static mode with an effective diffusion area 2.8cm2. The capacity of receptor 
compartment  was  200ml  and  temperature  was  maintained  at  370c+1  by 
means of temperature controller of magnetic stirrers. Drug concentration in 
donor compartment was 7.473mg/ml Receptor solution was 0.1mHCl which 
was continuously stirred at 100 rpm with a Teflon – coated bar movement 
placed inside the cell.
Dialysis  membrane  was  mounted  between  donor  and  receptor 
compartment of the cells and lower side of membrane is in direct contact 
with the receptor medium. After fixing of patch on membrane, the 5ml of 
solution withdrawn at specific time interval and  equal volume of 0.1N HCl 
added  to  receptor  solution  in  an  attempt  to  maintain  drug  concentration 
constant through out the experiment (24 hrs). The amount of drug permeated 
from receptor solution at predetermined times were analyzed by UV-visible 
spectrophotometer.
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In vitro diffusion study10,62
The in vitro release profile of Amlodipine from a transdermal device 
was determined. An open tubular cell was used for the diffusion studies. The 
dialysis membrane was mounted between donor and receptor compartment 
of diffusion. The receptor compartment of the diffusion cell was filled with 
0.1NHCl. The prepared matrix patch was placed over the membrane. The 
temperate  of  the  receptor  compartment  was  maintained  at  37±10C.  The 
receptor solution was stirred with Teflon coated magnet stirrer through out 
the experiment. Aliquots of receptor fluid were withdrawn at predetermined 
time intervals and replaced immediately with same volume of the fresh fluid, 
the samples were analyzed at 365 nm using spectrophotometrically.
In vivo release studies65
In vivo release studies were carried out using both gender rabbits for 
transdermal patch containing hydroxy propyl methyl cellulose as polymer 
and dimethylsulpoxide (DMSO). Four rabbits weighing 1.5 to 2.0kg were 
selected and the dorsal surface was cleaned and hair was removed. Trans 
dermal patch of 2.8cm2 having dose equivalent to 7.473mg were placed with 
the help of adhesive tape. Blood samples (0.5ml) were with drawn from the 
marginal ear (cuboidal vein) into heparinized glass vessels at 0, 0.50, 1, 2, 4, 
6,  8,  12,  24  and  48  hrs..The  plasma  was  separated  immediately  by 
centrifugation  at  2000  rpm  for  10min  and  stored  in  refrigerator  until 
analysis. The absorbance of the solution was measured at 365nm against a 
blank 
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Skin irritation test
A primary skin irritation test was performed since skin is vital organ 
through which drug is transported. The test was carried out on eight healthy 
rabbits  weighing 1.5 to  2.0 kg.  Drug free polymeric    films  of  diameter 
2.8cm2  containing dimethylsulphoxide as a penetrant were used as control. 
The dorsal surface of rabbits was cleared well and the hair was removed by 
using a fresh blade. The skin was cleared with rectified spirit. Transdermal 
patches  containing amlodipine  (7.47mg equivalent)  in  HPMC were place 
over the skin with the help of adhesive tape. The films and patches were 
removed after 48hrs and the skin was examined for erythema / oedema. All 
the experimental  protocol involving laboratory animals were approved by 
the IAEC. 
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6.8  ACCELERATED    STABILITY   STUDIES 90
Stability 
                  Stability is officially defined as the time lapse during which the 
drug product retains the same properties and characteristics that is possessed 
at the time of manufacture. This process begins at early devolvement phase.
       Instability  in  modern  formulation  is  often  detectable  only  after 
considerable storage period under normal condition. To assess the stability 
of a formulated product its usual to expose it to high stress conditions to 
enhance its detoriation and therefore the time required for testing is reduce
 common high stress like temperature and humidity. This will eliminate 
unsatisfactory formulation.
Strategy of stability testing 
1. The study of drug decomposition kinetics
2. The development of stability dosage form.
3. Establishment  of  expiration  date  for  commercially  available  drug 
product is some of the needs of stability testing.
4. Data form stability studies should be provided on atleast three primary 
batches of the drug product. 
5. The batches should be manufactured to a minimum of pilot scale.
6. Important point of view of the safety of the patient, patient relieves a 
uniform dose of drug throughout the shelf life of the product.
130
Table No.4The Stability Storage condition
S.No Study Storage condition Minimum 
period
1. Long-term study 25° C ± 2° C 
60 % ± 5% RH
12 month
2. Intermediate study 30 ° C ± 2° C
60 % ±5 % RH
6 month
3. Accelerated study 40° C ± 2 ° C
75% ±5 % RH
6 month
ICH (International Conference on Harmonization) Guidelines
 Specification
1. 5% potency loss from initial assay of batch
2. Any specification degradation that exceed specification
3. Product failing out of pH limit
4. Dissolution out of specification for 12 minutes
5. Failure to meet specification for appearances and physical properties
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Any one condition is observed then the stability of the batch is failed.
Procedure
Stability  studies  were  carried  out  using  temperature  controlled 
environment  test  chamber  according  to  ICH  guidelines  by  storing  the 
formulated films (F2) at 400c / 75 + 5% RH for a period of 3 months. The 
samples  were  withdrawn at  30,  60  and 90 days  and analysed  for  drug 
content by spectrophotometrically.
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7. Results and Discussion
Preformulation Studies
Drug Identification
      Method - Spectrophotometer method (UV)
Table No.5 UV- Absorbance of Amlodipine Besylate in 0.1 N HCl
S. 
No
Concentration in 
mcg/ml
Absorbance at 
365nm
1 25 mcg/ml 0.281
Discussion
 
The UV- absorbances of the Amlodipine besylate were performed at 
25 mcg/ml  concentration in  0.1 N HCl and their  wavelength  were 
found and compared with monograph. 
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Figure No.7 UV- Absorbance of Amlodipine Besylate in 0.1 N HCl
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Infra-Red Spectrum
Table No.6 IR Spectrum of Amlodipine Besylate
S.No Frequency cm-1 Functional Group
1 3411 NH Stretching 
2 2813 CH-aliphatic 
3 1672 C=0 ester 
4 561 C - C1 (C1 vibration) 
5 1120 - C- 0 - ester 
6 1382 – C - CH3
7 1593 - C = C - aromatic 
8 756 Mono substituted aromatic 
9 1208 C - 0 Stretching 
10 1204 Phenolic  Stretching 
Discussion
• The structure of Amlodipine Besylate was confirmed by IR 
spectrum (performed by KBr pellet method).
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Figure No.8 IR Spectrum of Amlodipine Besylate
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Compatibility Studies
DSC Graph for Amlodipine Besylate Patch
Discussion
Differential  scanning calorimetry (DSC) was used for compatibility 
studies between the drug and the excipients. The DSC graph shows that the 
drug and the excipients are compatible with each other as no elimination of 
endothermic peak occur and the melting point of drug was also seen in the 
DSC graph of transdermal film. From above all, the interpretation conclude 
that the drug and excipients (HPMC) are compatible with each other when 
they are in the film form
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 Figure No.9 DSC Graph for Amlodipine
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                             Figure No.10. DSC Graph for HPMC 
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Figure No.11 DSC Graph for  Amlodipine  Besylate Patch
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In vitro Drug Release Profile 
Diffusion  profile for Amlodipine Besylate in 0.1 N HCl 
Table No. 7 In vitro release profile F2 Formulation 
S.No Time in hrs Absorbance 
in nm
Concentration 
in mcg/ml
Amount 
in
mg
% Drug 
release
01 0 0 0 0 0
02 0.25 0.035 0.954 0.191 2.55
03 0.50 0.046 1.946 0.389 5.20
04 1.00 0.065 3.658 0.732 9.79
05 1.50 0.091 6.055 1.210 16.17
06 2.00 0.121 8.703 1.740 23.28
07 3.00 0.135 9.963 1.992 26.5
08 4.00 0.146 10.954 2.190 29.30
09 6.00 0.157 11.945 2.389 31.96
10 8.00 0.170 13.117 2.623 35.09
11 12.00 0.194 15.279 3.055 40.81
12 16.00 0.220 17.621 3.524 47.10
13 24.00 0.265 21.675 4.335 57.94
Figure No.12 In vitro Drug Release Profile for F2 Formulation
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Table No.8 In Vitro Release Profile F3 Formulation 
S.No Time in hrs Absorbance 
in nm
Concentration 
in mcg/ml
Amount 
in
mg
% Drug 
release
01 0 - - - -
02 0.25 0.008 - - -
03 0.50 0.017 - - -
04 1.00 0.025 0.054 0.010 0.13
05 1.50 0.034 0.872 0.174 2.32
06 2.00 0.041 1.495 0.299 4.00
07 3.00 0.062 3.387 0.677 9.05
08 4.00 0.078 43828 0.965 12.91
09 6.00 0.095 6.360 1.272 17.02
10 8.00 0.118 8.432 1.686 22.56
11 12.00 0.147 11.045 2.209 29.55
12 16.00 0.179 13.927 2.785 37.26
13 24.00 0.210 16.720 3.344 44.74
Figure No.13 In vitro Drug Release Profile for F3 Formulation
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Table No. 9 In Vitro Release Profile F4 Formulation 
S.No Time in hrs Absorbance 
in nm
Concentration 
in mcg/ml
Amount 
in
mg
% Drug 
release
01 0 - - - -
02 0.25 0.008 - - -
03 0.50 0.012 - - -
04 1.00 0.024 - - -
05 1.50 0.030 0.504 0.100 1.33
06 2.00 0.041 1.495 0.288 4.00
07 3.00 0.055 2.756 0.551 7.37
08 4.00 0.069 4.018 0.803 10.74
09 6.00 0.080 5.009 1.001 13.39
10 8.00 0.097 6.540 1.308 17.50
11 12.00 0.120 8.612 1.722 23.04
12 16.00 0.154 11.675 2.335 31.24
13 24.00 0.171 13.207 2.641 35.34
Figure No.14 In vitro Drug Release Profile for F4  Formulation
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Figure No.15 Comparative In vitro Drug Release Profile 
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In vivo Drug Release Profile 
Table No.10  In Vivo Release Profile Control Formulation
∑ AUC = 2183.92    
∑ AUMC = 53481.1849
Tim
e in 
hrs 
(t)
Absorban
ce in nm
Plasma 
drug 
concentrati
on µg / ml 
Amou
nt of 
drug 
in mg
% 
Drug 
releas
e 
C T [AUC]t 0
µghr/ml
[AUMC]t 0
µghr2/ml
0 0 - - - - 1.995 0.9976
0.50 0.113 7.981 0.798 7.98 3.990 6.918 5.9208
1.00 0.243 19.693 1.969 19.69 19.693 24.513 39.1765
2.00 0.350 29.333 2.933 29.33 58.666 65.062 201.582
4.00 0.421 35.729 3.572 35.72 142.916 76.143 385.4
6.00 0.473 40.414 4.041 40.41 242.484 83.531 587.42
8.00 0.503 43.117 4.311 43.11 344.936 184.9 1873.864
12.0
0
0.572 49.333 4.933 49.33 591.996 608.754 11058.12
24.0
0
0.603 52.126 5.212 52.12 1251.02
4
1132.104 39328.704
48.0
0
0.493 42.216 4.221 42.21 20.26.3
68
0 0
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Figure No.16 In vivo Drug Release Profile for control Formulation
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Table No: 11  Pharmacokinetic Parameter  for Control
Pharmacokinetic Parameter Values
KE 0.0801 hr-1
t ½ 8.65 hrs
Cmax 52.126 mcg/ml
tmax 24 hrs
[AUMC] 48 0 85375.412 mcg hr2/ml
[AUC] 48 0 2711.62 mcg hr/ml
MRT 31.485 hrs
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Table No.12 In Vivo Release Profile F2 Formulation 
∑ AUC = 1687.0812 
∑ AUMC = 44405.0229
Time 
in 
hrs 
(t)
Absorbance 
at 365 nm
Plasma drug 
concentration 
µg / ml
Amount 
of drug 
in mg
% 
Drug 
releas
e
C T [AUC]t 0
µghr/ml
[AUMC]t 
0
µghr2/ml
0 0 - - - - 0.4187 0.2093
0.50 0.043 1.675 0.167 2.24 0.8375 1.2205 1.0111
1.00 0.060 3.207 0.320 4.29 3.207 4.153 6.7025
2.00 0.081 5.099 0.509 6.82 10.198 14.071 46.086
4.00 0.124 8.972 0.897 12.00 35.888 26.323 139.994
6.00 0.217 17.351 1.735 23.21 104.106 44.161 318.586
8.00 0.322 26.810 2.681 35.87 214.48 135.89 1416.2
12.0
0
0.481 41.135 4.113 55.04 493.62 509.292 9261.288
24.0
0
0.510 43.747 4.374 58.54 1049.92
8
951.552 33075.36
48.0
0
0.419 35.549 3.554 47.57 1706.35
2
0 0
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Figure No.17 In vivo Drug Release Profile for F2 Formulation
In vivo Drug Release
0
5
10
15
20
25
30
35
40
45
50
0 10 20 30 40 50 60
Time in hours
Pl
as
m
a 
Dr
ug
 c
on
ce
nt
ra
tio
n 
in
 m
cg
/m
l
F2
152
153
Table No. 13 Pharmacokinetic Parameter for Formulation F2
Pharmacokinetic 
Parameter
Values
KE 0.1059 hr-1
t ½ 6.54 hrs
Cmax 43.747 mcg/ml
tmax 24 hrs
[AUMC] 48 0 63887.720 mcg hr2/ml
[AUC] 48 0 2022.765 mcg hr/ml
MRT 31.584 hrs
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Table No.14 In Vivo Release Profile F3 Formulation 
∑ AUC = 1481.67   
  
∑ AUMC = 10837.3969
Time 
in 
hrs 
(t)
Absorbance 
at 365 nm
Plasma drug 
concentration 
µg / ml 
Amount 
of drug 
in mg
% 
Drug 
releas
e 
C T [AUC]t 0
µghr/ml
[AUMC]t 
0
µghr2/ml
0 0 - - - - 0.1485 0.07425
0.50 0.031 0.0594 0.0594 0.703 0.297 0.725 0.6507
1.00 0.050 0.230 0.230 3.08 2.306 3.2215 4.99
2.00 0.067 3.383 0.383 5.13 7.674 7.4675 36.718
4.00 0.105 0.726 0.726 9.71 29.044 21.188 112.606
6.00 0.179 1.392 1.392 18.63 83.562 36.503 264.17
8.00 0.275 2.257 2.257 30.21 180.608 110.484 1145.2
12.0
0
0.387 3.266 3.266 43.71 391.992 431.454 8002.944
24.0
0
0.460 3.924 3.924 52.51 941.832 870.48 1270.044
48.0
0
0.394 3.329 3.329 44.55 1598.25
6
0 0
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Figure No.18 In vivo Drug Release Profile for F3 Formulation
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Table No. 15 Pharmacokinetic Parameter  for Formulation F3
Pharmacokinetic Parameter Values
KE 0.09212 hr-1
t ½ 7.532 hrs
Cmax 39.243 mcg/ml
tmax 24 hrs
[AUMC] 48 0 32119.593 mcg hr2/ml
[AUC] 48 0 1843.200 mcg hr/ml
MRT 17.425 hrs
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Table No.16 In Vivo Release Profile F4 Formulation 
Time 
In Hrs 
(T)
Absorban
ce
at 365 nm
Plasma 
Drug 
Concentrat
ion µg / Ml 
Amount 
Of Drug 
In mg
% Drug 
Release 
C T [Auc]t0
µghr/
Ml
[Aumc]t0
µghr2/Ml
0 0 - - - - 0.126 0.063
0.50 0.030 0.504 0.050 0.67 0.252 1.565 0.5945
1.00 0.048 2.126 0.212 2.84 2.126 2.8015 4.54
2.00 0.063 3.477 0.347 4.65 6.954 7.585 23.386
4.00 0.070 4.108 0.410 5.49 16.43
2
14.702 79.996
6.00 0.142 10.594 1.059 14.17 63.56
4
26.684 192.284
8.00 0.203 16.090 1.609 21.53 128.7
2
78.052 807.904
12.00 0.279 22.936 2.293 30.69 275.2
32
313.61
4
5875.344
24.00 0.350 29.333 2.933 39.25 703.9
92
629.4 21763.29
6
48.00 0.281 23.117 2.311 30.93 1109.
616
0 0
∑ AUC =1074.5295
∑ AUMC = 28747.4075
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Figure No.19 In vivo Drug Release Profile for F4 Formulation
in vivo Drug Release
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Table No. 17 Pharmacokinetic Parameter  for F4 Formulation
Pharmacokinetic Parameter Values
KE 0.1287 hr-1
t ½ 5.384 hrs
Cmax 29.333 mcg/ml
tmax 24 hrs
[AUMC] 48 0 38764.775 mcg hr2/ml
[AUC] 48 0 1254.148 mcg hr/ml
MRT 30.90 hrs
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Figure No. 20 Comparative In vivo Drug Release Profile 
In vivo Drug Release Profile
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Skin Irritation Studies
The  results  of  the  skin  irritation  studies  indicate  that  neither  the 
adhesive nor Amlodipine have any noticeable irritation on the rabbit skin for 
the 48 hours study periods.  
Stability Studies
Stability  studies  revealed  that  the  drug  content  in  formulation  F2, 
degraded respectively by 0.76%, 1.40% and 1.90% in a period of 90 days.
Table No.14 Stability studies for F2 Formulation 
Time period in 
month
Drug Content %
Initial 99.24
1st Month 99.14
2nd  Month 98.60
3rd Month 98.10
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8. SUMMARY AND CONCLUSION
The formulation of transdermal films were prepared using different ratio 
of  the  same  polymers  which  assigned  in  increasing  order  according  to 
permeation rates F2>F3> F4. The results indicate that the films prepared with 
hydroxy proplymethyl cellulose as polymer of 1:4 (Drug: HPMC) F2 was found 
to  be  best  during  in  vitro  study.  Hence  conclude  that  the  increase  in  the 
concentration of polymer and film thickness decreases the drug release profile.
The in vivo studies demonstrate  the transdermal  drug delivery system 
gives sustained plasma concentration and avoids wide fluctuation of  plasma 
concentration of amlodipine in rabbit. 
♦ From the IR interpretation and UV- results the sample confirmed to be of 
amlodipine besylate. 
♦ Melting  point,  partition  coefficient,  and  solubility  determined 
experimentally and molecular weight taken from literature.
♦ All physicochemical character support that the drug amlodipine may be 
suitable for transdermal drug delivery system.
♦ DSC  studies  carried  out  and  it  support  the  drug  and  excipient  was 
compatible when they were in film form. 
♦ In  vitro  studies  carried  out  using  F2,  F3 and  F4 formulation  as  F1 
formulation  polymer  concentration  not  sufficient  to  form  a  film.  F2 
formulation shows better release than F3 and F4. 
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In vivo studies carried out also using F2, F3 and F4 and better release was 
shown only by F2 formulation. The in vivo studies demonstrate the transdermal 
drug  delivery  system  gives  sustained  plasma  concentration  and  avoid  wide 
fluctuation of plasma concentration of amlodipine in rabbits as diffusion of the 
drug was extended over a long period at control rate and it followed a pattern 
close to zero order release profile. 
The results of the skin irritation studies indicate that neither the adhesive 
nor amlodipine have any noticeable irritation on the rabbit skin for the 48 hours 
study  periods.  Skin  irritation and /  or  edema was not  observed during skin 
irritation test. Hence, amlodipine films can be used in long term management of 
cardio  vascular  diseases,  necessitating  long  term  therapy  by  nullifying  the 
common adversities of the drug. 
Stability studies revealed that the drug content in formulation F2 degraded 
respectively by 0.76%, 1.40% and 1.90% in a period of 90 days.
Hence,  finally  conclude  that  the  study  shows  the  feasibility  of 
formulating  rate  controlled transdermal  drug delivery system for  amlodipine 
besylate  in  order  to  achieve  improved  bioavailability  and  nullifying  the 
common adversities of the drug. 
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